Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LPCN by emailGet an email when LPCN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LPCN, unsubscribe in one click. Privacy
📣 What LPCN Says Is Next
in 2026 · “Data from this Phase 3 trial are expected to support a 505(b)(2) NDA submission for LPCN 1154 in 2026.”
Company press release, Feb 18, 2026 · SEC filing
in 2026 · “The Phase 3 trial is expected to support a global registration package for LPCN 1154 in PPD, including a 505(b)(2) New Drug Application (NDA) submission in the U.S. which is expected in 2026.”
Company press release, Nov 6, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LPCN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LPCN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.